Home / Stock ratings / BDX

Stock rating · Surgical & Medical Instruments & Apparatus

Becton, Dickinson and Co. (BDX) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Becton, Dickinson and Co. 60 out of 100 (Runner!). Its highest factor score is price momentum at 79, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-20

BDX · composite score

60/100
Runner!
Nov 20
Rating date
Live price in the app →
Quality45
Momentum79
Risk-adjusted55
Source basis SEC filings and live market dataDated snapshot

About Becton, Dickinson and Co.

Becton Dickinson operates in four business units. Medical essentials (35% of total sales) is the legacy medical surgical unit selling catheters, syringes, and infection prevention products. Connected care (24%) includes the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) makes prefillable syringes and autoinjectors. Interventional (29%) covers surgery, peripheral vascular, and urology. More than 60% of revenue comes from the US.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why BDX scores 60/100

BDX's 8 factor scores run from 36 to 79, and 3 of them sit above its composite of 60. Here is how BDX breaks down.

Valuation57/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 15.0x, earnings growth accelerating
Business quality45/100

Margins, returns on capital, and balance-sheet strength.

Price momentum79/100

Direction and relative strength of the recent share-price trend.

  • Price +9.4% above 50-day MA
  • 50-day MA above 200-day (golden cross zone)
Earnings track record74/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
Analyst sentiment63/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile55/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How BDX compares

As of November 20, 2026, Becton, Dickinson and Co. ranks 5th of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 62.

All stock rating pages.

Key risks for BDX

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt
  • Trading near 52-week high, limited upside without new positive catalyst

Sector and theme context

Becton, Dickinson and Co. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds BDX's momentum and catalyst factors above.

BDX trade plan (Pro)

MELANY has a full position plan for Becton, Dickinson and Co.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates BDX

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Becton, Dickinson and Co.'s 60/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about BDX

Is Becton, Dickinson and Co. (BDX) a buy?

As of 2026-11-20, MELANY rated Becton, Dickinson and Co. Runner! with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does BDX rank against similar companies?

As of November 20, 2026, Becton, Dickinson and Co. ranks 5th of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 62. Among the other names in the group, the highest scores belong to DXCM (69) and TFX (67).

Should I buy Becton, Dickinson and Co. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Becton, Dickinson and Co. (BDX) Runner! with a composite of 60/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the BDX stock price forecast?

MELANY does not publish price targets or forecasts for BDX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Becton, Dickinson and Co., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for BDX as of 2026-11-20: its analyst sentiment factor is 63/100, and its price momentum factor is 79/100.

Is BDX stock overvalued or undervalued?

MELANY's valuation factor currently reads 57/100 for Becton, Dickinson and Co., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BDX's read.

What price should I buy BDX at?

Rather than chasing the current price, MELANY computes a smart entry zone for BDX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying BDX stock?

The top risks MELANY currently flags for Becton, Dickinson and Co.: Performance partly driven by Healthcare sector, rotation away from this theme would hurt; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Becton, Dickinson and Co. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 45/100 for Becton, Dickinson and Co., and earnings track record, at 74/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will BDX stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 79/100 for BDX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this BDX rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores BDX as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, BDX included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.